| Ironwood Pharmaceuticals pursues clinical candidates with the greatest potential to make a difference in patients’ lives. We have a commitment to continually evaluate the emerging product profile and market potential of each drug candidate throughout the development process, enabling us to focus our efforts on the most promising candidates.
Our clinical programs currently include several development candidates—linaclotide, in clinical testing for irritable bowel syndrome with constipation and chronic constipation, and novel cholesterol absorption inhibitors for the treatment of high cholesterol. Our discovery efforts continue to produce a promising pipeline of new clinical candidates in areas such as gastrointestinal and cardiovascular diseases, pain, and inflammation.
|
